| 2026-02-06 | +74.4% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-02-06 | +74.4% | news | Investing.com | Pulse Biosciences stock rises after positive cardiac catheter study data - Investing.com |
| 2026-02-06 | +74.4% | news | Benzinga | Pulse Biosciences Heart Device Data Fuels Stock Surge - Benzinga |
| 2026-02-06 | +74.4% | news | TipRanks | Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Study Results - TipRanks |
| 2026-02-06 | +74.4% | news | Investing.com Canada | Pulse Biosciences stock rises after positive cardiac catheter study data By Investing.com - Investing.com Canada |
| 2022-02-08 | -43.0% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-02-05 | +36.7% | news | Stock Titan | AF heart study in 150 patients reports 96% success at 1 year - Stock Titan |
| 2022-05-11 | -34.8% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2023-03-30 | +31.9% | legal | SEC EDGAR | PLSE 8-K: 2.02, 5.02 (SEC Filing) |
| 2022-03-31 | -27.2% | legal | SEC EDGAR | PLSE 8-K: 2.02, 2.05 (SEC Filing) |
| 2024-05-20 | +24.2% | news | Seeking Alpha | Pulse Biosciences announces updated timing of rights offering for up to $60M |
| 2024-05-20 | +24.2% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2024-07-08 | +22.1% | legal | Seeking Alpha | Pulse stock rallies 22% on FDA breakthrough designation |
| 2024-07-08 | +22.1% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-04-07 | -19.5% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-04-07 | -19.5% | news | Trefis | Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock - Trefis |
| 2026-04-07 | -19.5% | earnings | MarketBeat | Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 11.7% - Here's Why - MarketBeat |
| 2026-04-07 | -19.5% | news | Stock Titan | First patients treated in Pulse Biosciences (NASDAQ: PLSE) NANOPULSE-AF AFib trial - Stock Titan |
| 2026-04-07 | -19.5% | news | Stock Titan | First 7 patients get Pulse catheter in pivotal AFib trial - Stock Titan |
| 2025-02-04 | +19.4% | executive | Seeking Alpha | Pulse Biosciences appoints Jon Skinner as CFO |
| 2025-02-04 | +19.4% | legal | SEC EDGAR | PLSE 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-02-20 | -19.2% | earnings | Seeking Alpha | Pulse Biosciences slips despite Q4 beat after deal to sell shares |
| 2026-02-20 | -19.2% | earnings | Seeking Alpha | Pulse Biosciences targets CE Mark submission in 2026 as nPulse platform advances clinical milestones |
| 2026-02-20 | -19.2% | earnings | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript |
| 2026-02-20 | -19.2% | earnings | Seeking Alpha | Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha |
| 2026-02-20 | -19.2% | news | Stock Titan | New hires at Pulse Biosciences get 19,000 stock options - Stock Titan |
| 2026-04-16 | +17.7% | news | Stock Titan | Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan |
| 2024-02-14 | +16.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-02-19 | -16.3% | earnings | Seeking Alpha | Pulse Biosciences GAAP EPS of -$0.26 beats by $0.05, revenue of $0.26M beats by $0.01M |
| 2026-02-19 | -16.3% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-02-19 | -16.3% | legal | SEC EDGAR | PLSE 8-K: 1.01, 1.02 (SEC Filing) |
| 2026-02-19 | -16.3% | earnings | Yahoo Finance | Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2026-02-19 | -16.3% | expansion | TradingView | Pulse Biosciences Launches $59.98 Million ATM Equity Program With TD Cowen - TradingView |
| 2026-02-19 | -16.3% | earnings | AlphaStreet | Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited - AlphaStreet |
| 2024-10-31 | -16.3% | earnings | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript |
| 2024-10-31 | -16.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2024-01-02 | -16.2% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-02-08 | +16.2% | news | Yahoo Finance | We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate - Yahoo Finance |
| 2026-02-07 | +16.2% | news | Trefis | Pulse Biosciences Stock Pre-Market (+5.5%): Searching for a Catalyst - Trefis |
| 2024-06-07 | -16.0% | legal | SEC EDGAR | PLSE 8-K: 5.02 and 5.07 (SEC Filing) |
| 2022-12-06 | +15.5% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2026-02-09 | +15.1% | news | Investing.com | Pulse Biosciences stock hits 52-week high at 22.76 USD - Investing.com |
| 2026-02-09 | +15.1% | news | Zacks Investment Research | PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data - Zacks Investment Research |
| 2026-04-17 | +14.7% | analyst | Business Wire | Pulse Biosciences to Host Analyst Event on April 25, 2026 |
| 2026-04-17 | +14.7% | earnings | MarketBeat | Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% Higher - Here's Why - MarketBeat |
| 2026-04-17 | +14.7% | news | Stock Titan | Pulse Biosciences to discuss new AFib catheter data on April 25 - Stock Titan |
| 2025-08-13 | +14.3% | earnings | Seeking Alpha | Pulse Biosciences outlines initial percutaneous electrode revenue and IDE milestones while expanding nsPFA clinical programs |
| 2025-08-13 | +14.3% | earnings | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript |
| 2025-09-15 | +14.2% | legal | Yahoo Finance | How Investors Are Reacting To Pulse Biosciences (PLSE) Gaining FDA Clearance for NANOCLAMP AF Study - Yahoo Finance |
| 2022-04-14 | -14.1% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2022-05-04 | -12.5% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2023-05-01 | +12.1% | legal | SEC EDGAR | PLSE 8-K: 1.01, 1.02, 3.02, 8.01 (SEC Filing) |
| 2024-03-11 | +11.7% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-02-03 | +11.5% | news | DirectorsTalk Interviews | Pulse Biosciences, Inc. (PLSE) Stock Analysis: Unlocking a 71% Upside Potential in Bioelectric Medicine - DirectorsTalk Interviews |
| 2025-08-12 | +11.4% | earnings | Seeking Alpha | Pulse Biosciences GAAP EPS of -$0.28 misses by $0.02 |
| 2025-08-12 | +11.4% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2022-09-28 | +11.3% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2022-09-23 | +11.0% | legal | SEC EDGAR | PLSE 8-K: 1.01, 2.03, 2.05, 5.02 (SEC Filing) |
| 2024-08-08 | +11.0% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2023-11-13 | +10.9% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2024-05-07 | -10.9% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-02-17 | +10.0% | legal | DirectorsTalk Interviews | Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a Potential 12.99% Upside in the Healthcare Sector - DirectorsTalk Interviews |
| 2026-02-17 | +10.0% | news | Investing.com | Pulse Biosciences CCO Danahy sells $1.41 million in stock - Investing.com |
| 2026-03-12 | +9.9% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-03-12 | +9.9% | news | Stock Titan | Minimally invasive thyroid cancer study tests alternative to surgery - Stock Titan |
| 2022-06-09 | -9.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2022-08-16 | -9.1% | analyst | TradingView | PLSE Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-05-05 | -9.1% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2025-10-10 | -8.8% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2025-10-10 | -8.8% | news | MassDevice | Pulse Biosciences shares strong first-in-human PFA data - MassDevice |
| 2026-01-04 | +8.4% | news | AD HOC NEWS | Pulse Biosciences Is Exploding: Game-Changer Tech or Just Stock Market Cap? - AD HOC NEWS |
| 2022-03-21 | -8.0% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2021-08-09 | +7.9% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2021-08-20 | +7.4% | legal | SEC EDGAR | PLSE 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-03-27 | +7.3% | earnings | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript |
| 2025-03-27 | +7.3% | earnings | Seeking Alpha | Pulse Biosciences GAAP EPS of -$0.31 |
| 2024-05-09 | +7.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2025-01-13 | -7.1% | legal | SEC EDGAR | PLSE 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-10-01 | +6.8% | legal | SEC EDGAR | PLSE 8-K: 5.07 and 8.01 (SEC Filing) |
| 2025-10-01 | +6.8% | legal | Yahoo Finance | Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Yahoo Finance |
| 2023-11-21 | +6.7% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-04-08 | -6.7% | news | Seeking Alpha | Pulse Biosciences: Promising Catheter Technology, Weak Risk-Reward For Now |
| 2026-04-08 | -6.7% | news | Trefis | How Low Can PLSE Really Go In A Market Crash? - Trefis |
| 2026-04-08 | -6.7% | news | Seeking Alpha | Pulse Biosciences: Promising Catheter Technology, Weak Risk-Reward For Now - Seeking Alpha |
| 2026-03-27 | -6.7% | legal | SEC EDGAR | PLSE 8-K: 5.02 (SEC Filing) |
| 2026-03-27 | -6.7% | executive | TipRanks | Pulse Biosciences Grants RSUs to Chief Technology Officer - TipRanks |
| 2022-08-10 | +6.6% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-03-09 | +6.5% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-03-09 | +6.5% | news | Stock Titan | Experimental thyroid treatment shrank benign lumps 74% in 22 months - Stock Titan |
| 2024-08-12 | +6.4% | earnings | Seeking Alpha | Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript |
| 2024-08-12 | +6.4% | earnings | Seeking Alpha | Pulse Biosciences reports Q2 results |
| 2024-08-12 | +6.4% | legal | SEC EDGAR | PLSE 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-04-23 | -6.2% | news | Simply Wall St. | Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story |
| 2022-05-19 | -6.0% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2025-04-10 | +5.7% | news | Seeking Alpha | Pulse Biosciences: Some Key Questions Remain Unanswered |
| 2025-04-10 | +5.7% | earnings | Seeking Alpha | Pulse Biosciences: Interesting Product, But No Revenue Stream |
| 2025-04-10 | +5.7% | news | Seeking Alpha | Pulse Biosciences (PLSE) Stock: Some Key Questions Remain Unanswered - Seeking Alpha |
| 2025-12-18 | +5.6% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2023-05-10 | -5.6% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-04-13 | +5.6% | news | Zacks | Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study |
| 2026-04-13 | +5.6% | news | simplywall.st | Assessing Pulse Biosciences (PLSE) Valuation After Leadership Changes To Advance nPulse Cardiac Ablation System - simplywall.st |
| 2024-02-12 | -5.5% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-05-11 | -4.9% | earnings | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript |
| 2024-01-11 | -4.9% | news | Finimize | PLSE Stock Price | Pulse Biosciences Inc Stock Price | Index - Finimize |
| 2025-07-14 | -4.8% | legal | SEC EDGAR | PLSE 8-K: 5.02 (SEC Filing) |
| 2024-07-13 | +4.7% | news | intelligentinvestor.com.au | Pulse Biosciences (NASDAQ:PLSE) - intelligentinvestor.com.au |
| 2024-03-28 | -4.7% | legal | SEC EDGAR | PLSE 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-12-09 | +4.7% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2024-07-03 | +4.6% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2024-10-30 | +4.5% | earnings | Seeking Alpha | Pulse Biosciences reports Q3 results |
| 2024-10-30 | +4.5% | legal | SEC EDGAR | PLSE 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-08-26 | -4.5% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2022-11-10 | +4.4% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-03-17 | +4.3% | news | Seeking Alpha | Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System |
| 2026-03-17 | +4.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2025-03-28 | +4.1% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2024-05-11 | -4.0% | earnings | MarketBeat | Pulse Biosciences (PLSE) Stock Forecast and Price Target 2026 - MarketBeat |
| 2025-11-06 | -4.0% | earnings | Seeking Alpha | Pulse Biosciences targets Q1 completion of PRECISE-BTN study enrollment as clinical adoption grows |
| 2025-11-06 | -4.0% | earnings | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript |
| 2025-12-12 | +4.0% | news | Investing.com UK | Pulse Biosciences drops 38% after InvestingPro’s "Overvalued" warning By Investing.com - Investing.com UK |
| 2023-12-22 | +3.9% | legal | SEC EDGAR | PLSE 8-K: 5.07 and 8.01 (SEC Filing) |
| 2021-07-01 | +3.9% | legal | SEC EDGAR | PLSE 8-K: 1.01, 1.02, 3.02, 8.01 (SEC Filing) |
| 2026-03-03 | -3.8% | news | Stock Titan | Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck - Stock Titan |
| 2025-09-12 | +3.7% | news | Investing.com | Pulse Biosciences (PLSE) director Duggan buys shares worth $2.79 million - Investing.com |
| 2023-05-09 | +3.5% | legal | SEC EDGAR | PLSE 8-K: 1.01, 1.02and3.02 (SEC Filing) |
| 2025-01-23 | -3.5% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-03-04 | +3.4% | news | Stock Titan | Thyroid experts review 15–22 month data on Pulse nPulse ablation - Stock Titan |
| 2026-03-02 | -3.3% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2026-03-02 | -3.3% | executive | Stock Titan | Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation - Stock Titan |
| 2025-09-02 | -3.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-04-20 | +3.3% | news | Insider Monkey | Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial |
| 2026-04-20 | +3.3% | news | Business Wire | Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting |
| 2026-04-20 | +3.3% | news | Stock Titan | Pulse Biosciences brings one-year AFib data and live case to HRS 2026 - Stock Titan |
| 2026-04-20 | +3.3% | news | Yahoo Finance | Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Yahoo Finance |
| 2024-07-15 | +2.9% | legal | SEC EDGAR | PLSE 8-K: 1.01, 2.02 (SEC Filing) |
| 2021-11-24 | +2.7% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2025-11-10 | -2.7% | earnings | Yahoo Finance | Pulse Biosciences (PLSE) Is Down 7.9% After FDA OK for Cardiac Device Trials and Q3 Losses – Has the Bull Case Changed? - Yahoo Finance |
| 2026-04-10 | -2.6% | executive | MedTech Dive | Pulse Biosciences hires Liane Teplitsky as COO |
| 2026-04-10 | -2.6% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Pulse (PLSE) Stock Showing Weakness | Price at $17.90, Down 7.01% - Institutional Flow - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-09 | -2.6% | executive | MT Newswires | Pulse Biosciences Names Liane Teplitsky Chief Operating Officer |
| 2026-04-09 | -2.6% | news | Business Wire | Pulse Biosciences Strengthens Executive Leadership Team |
| 2026-04-09 | -2.6% | legal | SEC EDGAR | PLSE 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-09 | -2.6% | executive | Stock Titan | Pulse Biosciences (PLSE) hires new COO with large inducement equity grants - Stock Titan |
| 2026-04-09 | -2.6% | executive | Stock Titan | Pulse adds COO, full-time CMO to speed atrial fibrillation device push - Stock Titan |
| 2021-06-09 | -2.5% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-03-30 | +2.4% | earnings | MarketBeat | Pulse Biosciences (NASDAQ:PLSE) Shares Down 7% - What's Next? - MarketBeat |
| 2021-06-10 | -2.3% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2025-09-09 | -2.3% | legal | DirectorsTalk Interviews | Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 46% Potential Upside in the Medical Innovation Sector - DirectorsTalk Interviews |
| 2026-01-12 | -2.3% | news | Yahoo Finance | How Investors May Respond To Pulse Biosciences (PLSE) AF Data Reveal And Boardroom Refresh - Yahoo Finance |
| 2025-12-16 | +2.3% | legal | DirectorsTalk Interviews | Pulse Biosciences, Inc. (PLSE) Stock Analysis: A 55.70% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews |
| 2023-05-11 | -2.2% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-03-16 | +2.2% | news | Yahoo Finance | Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance |
| 2023-12-20 | -2.1% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2023-03-21 | -1.9% | legal | SEC EDGAR | PLSE 8-K: 1.01 and (SEC Filing) |
| 2026-02-27 | -1.9% | legal | SEC EDGAR | PLSE 8-K: 5.02 and (SEC Filing) |
| 2026-02-27 | -1.9% | executive | Stock Titan | Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute - Stock Titan |
| 2026-01-09 | -1.8% | legal | SEC EDGAR | PLSE 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-05-30 | +1.8% | legal | SEC EDGAR | PLSE 8-K: 5.02 and 5.07 (SEC Filing) |
| 2021-10-06 | +1.7% | legal | SEC EDGAR | PLSE 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-05-08 | +1.7% | earnings | Seeking Alpha | Pulse Biosciences GAAP EPS of -$0.25 |
| 2025-05-08 | +1.7% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-04-18 | +1.6% | news | Xã Vĩnh Công | Pulse (PLSE) Stock: Is It Moving in a Trend (Breakout Watch) 2026-04-18 - Asset Allocation - Xã Vĩnh Công |
| 2025-09-08 | -1.6% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2024-05-15 | +1.6% | legal | SEC EDGAR | PLSE 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-02-15 | +1.5% | legal | SEC EDGAR | PLSE 8-K: 5.02, 8.01 (SEC Filing) |
| 2024-06-28 | -1.4% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2025-10-24 | -1.4% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2022-06-03 | +1.3% | legal | SEC EDGAR | PLSE 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-11-05 | -1.3% | earnings | Seeking Alpha | Pulse Biosciences reports Q3 results |
| 2025-11-05 | -1.3% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2023-09-12 | -1.3% | legal | SEC EDGAR | PLSE 8-K: 5.02 (SEC Filing) |
| 2025-05-23 | -1.0% | news | Stock Titan | Pulse Biosciences Expands Team: 8,300 Shares in Stock Options Granted to New Technology Executives - Stock Titan |
| 2026-04-02 | -1.0% | news | Stock Titan | Needham healthcare conference to feature Pulse Biosciences on Apr. 16 - Stock Titan |
| 2026-04-02 | -1.0% | legal | Stock Titan | PLSE SEC Filings - Pulse Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2025-01-10 | -0.9% | executive | Seeking Alpha | Pulse Biosciences announces CEO appointment |
| 2022-01-11 | +0.8% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2026-04-04 | -0.7% | news | Stock Traders Daily | How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - Stock Traders Daily |
| 2026-04-03 | -0.7% | news | simplywall.st | Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge? - simplywall.st |
| 2026-04-03 | -0.7% | news | Stock Titan | Pulse Biosciences (PLSE) awards CTO 100,000 Restricted Stock Units - Stock Titan |
| 2026-04-03 | -0.7% | news | Cổng thông tin điện tử tỉnh Tây Ninh | PLSE Stock Analysis: Pulse Biosciences Inc 23 USD slight dip performance review - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2025-04-05 | +0.7% | news | Intellectia AI | PLSE Forecast — Price Prediction for 2026. Should I Buy PLSE? - Intellectia AI |
| 2024-05-02 | +0.7% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2021-11-15 | -0.7% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2024-12-26 | -0.6% | news | Seeking Alpha | Pulse Biosciences: Constructive On Nano-Pulse Assets |
| 2024-12-26 | -0.6% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2026-02-11 | -0.6% | news | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Presents at 31st Annual AF Symposium 2026 - Slideshow |
| 2026-03-01 | +0.6% | news | Yahoo Finance | Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts? - Yahoo Finance |
| 2026-01-15 | -0.5% | news | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2023-08-10 | -0.4% | legal | SEC EDGAR | PLSE 8-K: 2.02 and (SEC Filing) |
| 2023-07-20 | -0.4% | legal | SEC EDGAR | PLSE 8-K: 8.01 and (SEC Filing) |
| 2023-02-15 | +0.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Pulse Biosciences (PLSE) - Zacks Investment Research |
| 2026-04-12 | +0.4% | news | Simply Wall St. | Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? |
| 2026-04-12 | +0.4% | news | Yahoo Finance | Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? - Yahoo Finance |
| 2026-04-12 | +0.4% | news | simplywall.st | Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story? - simplywall.st |
| 2024-12-06 | +0.2% | legal | SEC EDGAR | PLSE 8-K: 5.02 (SEC Filing) |
| 2026-04-26 | — | analyst | Seeking Alpha | Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript |
| 2026-04-26 | — | news | simplywall.st | Assessing Pulse Biosciences (PLSE) Valuation After Positive nPulse Cardiac Catheter Study Update - simplywall.st |
| 2026-04-25 | — | news | Business Wire | Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026 |
| 2026-04-25 | — | news | Stock Titan | Atrial fibrillation catheter logs 60-minute procedures, 96% success - Stock Titan |